Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications - Wikidata - awgldk - TriplyDB

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

http://www.wikidata.org/entity/Q24685895

about

Invariant NKT cells as novel targets for immunotherapy in solid tumors Murine models to evaluate novel and conventional therapeutic strategies for cancer Immune Modulation in Hematologic Malignancies Lenalidomide and chronic lymphocytic leukemia New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)The regulatory role of invariant NKT cells in tumor immunity Future prospects of therapeutic clinical trials in acute myeloid leukemia.Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.A review of the history, properties, and use of the immunomodulatory compound lenalidomide.A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.Dose escalation of lenalidomide in relapsed or refractory acute leukemias.Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia The use of novel agents in the treatment of relapsed and refractory multiple myeloma Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Lenalidomide-induced acute interstitial nephritis Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.Immunotherapy of multiple myeloma: the start of a long and tortuous journey.Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer

P2860

Q21284987-272ED975-3F74-4455-AD65-5C01736A4F88 Q24673595-EEDC5C27-ED3A-48CA-A03E-99B4A2F3D967 Q26796307-145B874E-7760-4FF0-8B10-F3C2CDED8429 Q26823597-1FD2FC71-421E-40DE-84C9-2EBF137D97C7 Q27004421-024D5FA2-2F50-4917-B010-40D8B01C065F Q27023425-DA8A28DC-8A66-422E-ADE0-7133857D5CAC Q30244168-AB805FB3-0DB3-4C6D-ADDA-4EED1045F12E Q33396918-CFDD33C7-32F3-401B-AB93-7E5BEA39C13F Q33398019-F6CD944C-5600-4802-8A14-D5459DC07A79 Q33398044-DAF783C2-DDC1-4B86-A3AD-8273B88FE104 Q33399416-A194FAF9-F6A3-48A8-B974-D607B74F6F07 Q33403183-4A0A4D6C-1BF5-4E67-A783-84C54C6700F5 Q33413210-380367A8-583E-485C-A70E-1BD799F5028F Q33417117-3F1B4B3A-88E4-428F-B9F1-A43F4C22A984 Q33418964-655E8639-7282-410C-9CE5-2DAAB8037E30 Q33442755-93608C3E-7F3A-43E0-AF9A-73974364F9EF Q33707411-F32E4017-6CD9-4E2D-A6DB-1DD611D3AEA8 Q33817800-7CD0ADB3-B9CF-4C9D-BDF8-FCD2B5E0A009 Q33820610-8E493A38-A8CC-4525-B325-259FD7AE3FC0 Q33864162-E5348ADD-EC13-4471-80CF-8E24050FD3C9 Q34173071-39BDB3D8-1EC6-4679-8570-E76C045B7C4E Q34220013-33A9E017-7CBE-4522-86D8-24A4E0CE7930 Q34257912-31FAB6D9-2196-4D1D-8F63-3EB8D73DFFCD Q34278096-632F7559-0287-40EB-9848-FF9F97B2623A Q34488712-56891D9A-DD84-4E23-912B-D109DA3D626B Q34666858-B1EED00D-EDAD-45B5-B4C4-FAB8B5529BC7 Q34989602-64662272-E758-49C6-9768-FD824F2DD100 Q35033519-50A97107-B030-44D6-B1B9-578145BA0B9D Q35097319-09382076-FC45-41CE-A761-26959580E2A5 Q35127172-0F4A680F-9315-4FE4-90C0-3303F4648DEB Q35171777-2B6A6CC0-B692-4923-B740-61129E03EDAF Q35584263-F134A6C9-4B78-4D34-BFDE-D3E47603CFC5 Q35784505-0111322C-E560-45FD-9A6B-3A2339F1CC7A Q36003724-433F20B8-815D-459F-9AB7-B3F3CC97C226 Q36154837-61582A7A-2199-46A1-A0D4-F960E6AE7FDA Q36542800-CE4AA4BD-55C7-4595-AF16-9E0E1E6BA952 Q36689152-4859ECA1-182E-4E11-956B-77ECD5F02463 Q36712736-72A53477-4361-45F5-B1F5-D986C11B9C93 Q36806619-2FB016EA-0492-4ABE-A59E-AE39897C21D5 Q36835186-45E7EB84-8921-4E86-A82E-7DAEC793C222

P2860

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

http://www.wikidata.org/entity/Q24685895

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Enhancement of ligand-dependen ...... mide: therapeutic implications

@ast

Enhancement of ligand-dependen ...... mide: therapeutic implications

@en

Enhancement of ligand-dependen ...... mide: therapeutic implications

@nl

type

label

Enhancement of ligand-dependen ...... mide: therapeutic implications

@ast

Enhancement of ligand-dependen ...... mide: therapeutic implications

@en

Enhancement of ligand-dependen ...... mide: therapeutic implications

@nl

prefLabel

Enhancement of ligand-dependen ...... mide: therapeutic implications

@ast

Enhancement of ligand-dependen ...... mide: therapeutic implications

@en

Enhancement of ligand-dependen ...... mide: therapeutic implications

@nl

P1433

Q24685895-0E38CB84-FBAC-4008-967C-112AB2251951

P1476

Q24685895-FD5EDB57-F8D6-43F5-99EB-626319F17C87

P2093

Q24685895-0262B4CB-2005-456E-8BDF-3C4D3C8FEB40

Q24685895-02D8441A-D39C-483E-BCA7-A6942D12221D

Q24685895-07452CD1-A592-4DFA-B4E7-E39943533A5D

Q24685895-42234CED-242E-46C7-B4A8-BD1E6EC54912

Q24685895-8CE80B48-3B26-4133-A109-1AE685F01EFA

Q24685895-921F8BDB-CF3A-4805-9B7F-1F71A5E8EFBC

Q24685895-A128EA51-8B8B-4C3B-BED6-AB69AD2288B5

Q24685895-AF1C958C-0B35-4A1B-AAF0-F749A619A035

P2860

Q24685895-0A7C2507-E89D-48B1-957F-CC48EC3CE777

Q24685895-0F5CF4F6-69FF-455F-A416-5417E1BA3429

Q24685895-1BB71391-D743-42B7-9F5E-E5A5492D7AA8

Q24685895-1BC32D2E-3A12-465F-9785-38905AABE9E3

Q24685895-505E4571-D70E-4051-8A6E-8EEDADD1847A

Q24685895-567AA440-4A20-4E83-A645-0FD43525977C

Q24685895-5EE02B77-14AA-486B-9193-5CA697E82328

Q24685895-65CC9490-17AF-479E-81C2-E74CE105C6E1

Q24685895-7999D758-4AF4-4980-9A13-AC99FBB852CA

Q24685895-7CEDBC39-E11A-42CE-A8BF-7041E34B086F

P304

Q24685895-35CFE209-7D55-4C69-867A-B65EAFB9BB18

P31

Q24685895-E939CF14-32DE-4A26-A3C3-C60973CBFC2B

P356

Q24685895-F1F60BD4-1E48-4876-B55E-786B088A4198

P407

Q24685895-74C78230-3848-4E43-9B82-6AB795A99EA8

P433

Q24685895-5EBBD383-4596-4246-8FE4-D62CF4661EC4

P478

Q24685895-90BD2DFF-0C08-4D6B-B37C-CFD5388A5E76

P577

Q24685895-CC272F9B-D946-42CC-A78E-4B01CE099C04

P5875

Q24685895-E82CB924-1B8E-499A-A0CC-156BA04696A8

P698

Q24685895-06CB13FD-D10B-4EC8-BDCB-D8C206890ED6

P921

Q24685895-52393377-B88F-4FC4-B1D2-7904AA5F5639

P932

Q24685895-C9537E02-E176-4417-9646-645728929F18

P356

BLOOD-2005-10-4184

P1433

P1476

Enhancement of ligand-dependen ...... mide: therapeutic implications

@en

P2093

Amitabha Mazumder

http://www.w3.org/2001/XMLSchema#string

David H Chang

http://www.w3.org/2001/XMLSchema#string

Hani Hassoun

http://www.w3.org/2001/XMLSchema#string

Madhav V Dhodapkar

http://www.w3.org/2001/XMLSchema#string

Nancy Liu

http://www.w3.org/2001/XMLSchema#string

Stephen D Nimer

http://www.w3.org/2001/XMLSchema#string

Sundar Jagannath

http://www.w3.org/2001/XMLSchema#string

Virginia Klimek

http://www.w3.org/2001/XMLSchema#string

P2860

Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients.

Efficacy of lenalidomide in myelodysplastic syndromes.

Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells.

Antitumor activity of thalidomide in refractory multiple myeloma.

NKT cells - conductors of tumor immunity?

Toward an understanding of NKT cell biology: progress and paradoxes.

A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells.

P304

618-21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-10-4184

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7209088

http://www.w3.org/2001/XMLSchema#string

P698

16569772

http://www.w3.org/2001/XMLSchema#string

P921

P932

1895497

http://www.w3.org/2001/XMLSchema#string